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In this study we assessed diﬀerences in new and repeat prescriptions of psycho-tropics between patients receiving prescriptions
for drugs to treat a common chronic disease and people without such prescriptions. The study used the databases of two Dutch
health insurance companies (3 million people). We selected all Dutch men and women aged 45 and older who were registered
for six consecutive years (1999–2004). Our analyses both found a consistent relation between psycho-tropics on the one hand
and physical illness on the other. People with multi-morbidity were prescribed these drugs most often, especially men and those
younger than 65. Epidemiological studies showed a prevalence of depression among people with multi-morbidity to be twice as
high as among people without such conditions. According to recent guidelines non-drug treatment may be the ﬁrst therapy option
for patients with non severe depression. If prescribed for a long time, benzodiazepine prescriptions are especially known to be
addictive. Our data raise the question to what extent patients with a chronic physical disease suﬀering from co-occurring mental
problems are prescribed psycho-tropics in accord with the guidelines that also advise mental support in case of non severe mental
problems. Further research can answer this important question.
1.Introduction
The expenditures on antidepressants and benzodiazepines
represent a substantial burden on the Dutch health care
budget [1], which also indicates that a high and growing
number of patients in the Netherlands have been prescribed
these drugs. It has been suggested that especially antidepres-
sants have increasingly been prescribed for milder symptoms
of depression and without receiving psychotherapy [2, 3].
Although these drugs for many patients are helpful, they
also have, if prescribed inadequately, a number of adverse
side eﬀects [4]. Side eﬀects reported for benzodiazepines
include dependency, sedation, memory deﬁcits, impaired
alertness and balance, postural hypotension, risk of falling,
and withdrawal reactions. A growing number of studies
are reporting comparable adverse eﬀects for antidepres-
sants, especially among the non-severe cases [5]. Current
guidelines of the Dutch and British College of General
Practitioners recommend reticence in prescribing antide-
pressantsandbenzodiazepines[6–8].Thegrowingawareness
of the adverse eﬀects of benzodiazepines in particular has
led to intervention studies being designed to help people
without an indication for these drugs to end or reduce
their use [9, 10]. These studies suggest that especially elderly
people use these drugs against the guidelines. On the other
side, it is also known that many patients, especially those
with a physical condition are under diagnosed for their
mental problems [11]. In an aging population, an important
underlying determinant of mental health problems appears
to be the presence of chronic physical illness [12].
Remarkably, existing guidelines for the diagnosis and
treatment of the major chronic diseases, like arthritis,
diabetes, and cardiac or pulmonary disease, appear to merely
provide guidelines for the somatic disease and not for2 Depression Research and Treatment
the mental problems that frequently accompany them. On
the other hand, guidelines for the diagnosis and treatment of
depression always mention physical disease as a possible risk
factor for depressive disorder. For this reason and based on
the best available evidence, the National Institute for Health
and Clinical Excellence (NICE) recently published an update
of the NICE recommendations regarding the treatment of
depression,including aspecialfocusonadultswithachronic
physical health problem and co-occurring depression [13],
emphasizing the high prevalence of mental health problems
among patients with a chronic physical condition [14].
Attention to the mental health of this group of adults is
becoming increasingly important, as the percentage of the
population suﬀering from chronic degenerative diseases is
expected to rise in the aging Western societies.
With regard to benzodiazepines prescriptions, guidelines
recommend the use of these drugs for no longer than
6 weeks for patients without severe psychiatric problems.
Antidepressants guidelines recommend prescription periods
of 6–9 month or even more if recurrences show up.
Changes in the physical conditions of patients with a
chronic disease constitute a long-term risk factor for mental
problems in an increasing number of patients with these
conditions. Instead of exclusively being prescribed pills,
these patients are assumed to be much better served by
strengthening their ability to cope with their burden of
disease. Treatment with psychotropics conforming to the
existing guidelines, is considered to be a temporal relief of
the complaints [15]. Although primary care professionals
are well aware of the problem, they may sometimes feel
unable to do anything else than prescribe antidepressants
to the category of patients with one or more chronic
conditions [16]. In the Netherlands, 80% of all patients
with a depressive disorder receive antidepressants as the
only form of treatment, despite current recommendations
for a combination of antidepressants with psychotherapy
[2]. We used cross-sectional and longitudinal analysis to get
more insight in the prescription of antidepressants and/or
benzodiazepines in the Netherlands. Special attention will be
paid to diﬀerences between patients with diﬀerent chronic
diseases and people without these diseases. We tried to
answer the following research questions.
(1) Isthereanassociation between patient categoriesand
the number of prescriptions for antidepressants and
benzodiazepines? Are there any diﬀerences between
age and sex categories?
(2) What is the trend regarding new prescriptions? Are
there diﬀerences between patient categories, and do
these diﬀer between age and sex categories?
(3) What is the trend in repeat prescriptions of benzo-
diazepines? Are there any diﬀerences between patient
categories?
2. Methods
2.1. Design. We carried out a cohort study involving 6 annual
assessments for all eligible people who were registered with
two insurance companies for the entire study period.
2.2. Study Population. The population included 734,748
Dutch men and women, aged 45 and older, who were
registered with two insurance companies for the whole six-
year interval between 1 January 1999 and 31 December 2004.
This database only comprised people covered by compulsory
health insurance under the Dutch state health insurance
scheme. The database includes all prescriptions, using the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation [17].
The numbers in the tables are diﬀerent due to diﬀerences in
exclusion criteria for the various analyses (see next section)
2.3. Assessments
Psycho-Tropics Prescriptions. Prescriptions of benzodiazep-
ines and antidepressants were based on the respective ATC
codes.
Patient Classiﬁcation. Four categories of patients were dis-
tinguished, based on prescriptions of disease-speciﬁc med-
ication. The ﬁrst category included patients continuously
receiving prescriptions for diabetes, who were identiﬁed by
ATC codes A10A and A10B (n = 11,128; 1.5% of the total
population of 734.748 people). The second category received
prescriptions for pulmonary disease, based on ATC codes
R03A, R03B, and R03C (n = 20,871; 2.8%). The third
category received prescriptions for cardiovascular disease,
based on ATC codes C and B01 (n = 191,091; 26.0%). A
fourth category was labelled multimorbidity, as it included
patients with prescriptions for more than one of the above
diseases (based on the corresponding ATC codes (n =
44,366; 6.0%)) To improve the validity of this patient
classiﬁcation, we only included only patients receiving these
prescriptions in each of the six years. We assumed that
patients continuously receiving these prescriptions must
have the corresponding chronic condition. The remaining
category was the reference category without the diseases
deﬁned above (n = 467,292; 63,6% of the total popula-
tion), although we cannot exclude the presence of other
chronic diseases in this category.
Demographics. Data about age and sex were also available in
the database.
2.4. Analyses. Cross-sectional analyses were done to examine
whether the four classes of patients based on the data of 1999
diﬀered with regard to prescriptions for benzodiazepines
and antidepressants in 1999. Logistic regression was used to
compute sex- and age-adjusted odds ratios (Table 1). This
was also done separately for men and women and for those
y o u n g e ra n do l d e rt h a n6 5( Table 2). The results section
only mentions diﬀerences of more than .10 between odds
ratios for the categories, although smaller diﬀerences may
be also statistically signiﬁcant, due to the high numbers.
We then performed longitudinal analyses which excluded
those who had received benzodiazepines and antidepressant
prescriptions in 1999 and used the time interval until the
ﬁrst prescription in the 2000 to 2004 period as the outcome.
These analyses were done with Cox proportional hazards
analysis, which was also sex- and age-adjusted (Table 3).Depression Research and Treatment 3
Table 1: Odds ratios (95% conﬁdence interval (CI)) of receiving at least one benzodiazepines or antidepressant prescription in 1999.
N( % ) %
Men
Mean
age
At least one
benzodiazepines
prescription (%)
Odds ratio∗ (95% CI)
benzo-diazepines
prescription
At least one anti-
depressants
prescription (%)
Odds ratio∗ (95%
CI) for
antidepressants
prescription
Reference 467,292 (63.6) 41.8 57.5 16.5 1.00 5.9 1.00
Diabetes 11,128 (1.5) 46.0 62.2 19.2 1.15 (1.09–1.21) 6.7 1.27 (1.18–1.37)
Pulmonary 20,871 (2.8) 48.1 60.2 26.4 1.85 (1.79–1.91) 7.5 1.39 (1.32–1.47)
Cardiovascular 191,091 (26.0) 40.3 64.8 27.2 1.68 (1.66–1.71) 7.2 1.40 (1.37–1.43)
Multimorbidity 44,366 (6.0) 42.0 66.3 30.4 1.96 (1.91–2.00) 8.0 1.60 (1.54–1.66)
∗Odds ratio adjusted for age and sex.
Table 2: Odds ratios (95% conﬁdence interval (CI)) of receiving at least one benzodiazepines or antidepressant prescription in 1999,
analysed separately for men and women and for persons younger and older than 65.
Odds ratio∗ (95% CI) of at least one benzodiazepines
prescription
Odds ratio∗ (95% CI) of at least one antidepressants
prescription
Men Women Men Women
(14.1% of 306,129 (25.0% of 428,619 (4.5% of 306,129 (7.8% of 428,619
with prescription) with prescription) with prescription) with prescription)
Reference 1.00 1.00 1.00 1.00
Diabetes 1.16 (1.07–1.26) 1.14 (1.07–1.21) 1.31 (1.15–1.49) 1.24 (1.13–1.37)
Pulmonary 1.85 (1.76–1.95) 1.91 (1.83–1.99) 1.37 (1.25–1.51) 1.43 (1.34–1.53)
Cardiovascular 1.73 (1.69–1.78) 1.66 (1.63–1.69) 1.48 (1.42–1.54) 1.36 (1.33–1.40)
Multimorbidity 2.17 (2.09–2.26) 1.87 (1.82–1.92) 1.80 (1.69–1.93) 1.53 (1.46–1.60)
<65 years >=65 years <65 years >=65 years
(17.8% of 487,546 (25.7% of 247,202 (6.8% of 487,546 (5.8% of 247,202
with prescription) with prescription) with prescription) with prescription)
Reference 1.00 1.00 1.00 1.00
Diabetes 1.17 (1.09–1.24) 1.13 (1.05–1.21) 1.35 (1.23–1.48) 1.11 (0.98–1.26)
Pulmonary 1.97 (1.89–2.04) 1.73 (1.63–1.83) 1.52 (1.43–1.62) 1.13 (1.01–1.26)
Cardiovascular 1.72 (1.69–1.75) 1.65 (1.61–1.68) 1.50 (1.46–1.55) 1.23 (1.18–1.28)
Multimorbidity 2.15 (2.07–2.22) 1.85 (1.79–1.91) 1.83 (1.74–1.93) 1.37 (1.29–1.44)
∗Odds ratio adjusted for age and sex.
Analyseswereagaindoneseparatelyformenandwomenand
forthoseyoungerandolderthan65(Table 4).Thenumberof
years with 6–12 prescriptions for benzodiazepines was used
to estimate chronic use of benzodiazepines (Table 5)[ 18].
People with more than 12 prescriptions in one year were also
excluded from this analysis, because this might be indicative
of more serious addictive disorders.
3. Results
3.1. Prescriptions for Chronic Diseases and Psychotropics. We
found a clear relationship between classiﬁcation and the
prescriptionsofbenzodiazepinesandantidepressants.People
with medications for one of the chronic conditions were
more likely to receive prescriptions for benzodiazepines and
antidepressants than the reference category. The diﬀerences
for benzodiazepines were somewhat clearer than those for
antidepressants. We found that people with prescriptions for
diabetes were largely comparable to those from the reference
category, while those with medications for pulmonary and
cardiovascular disease occupied an intermediate position
between the reference category and those of the multimor-
bidity category.
Men in the multimorbidity category relatively (as com-
pared to their reference group) had a greater chance
of receiving prescriptions for benzodiazepines than their
female counterparts. The same holds for prescriptions for
antidepressants. People younger than 65 years with physical
illness had relatively (as compared to their reference group) a
greater chance of receiving benzodiazepines than older peo-
ple. This was especially true for people in the multimorbidity
category, and to a lesser extent for people in the pulmonary
category. People in all the younger age disease categories
had relatively a greater chance of receiving antidepressant
medication thantheiroldercounterparts. Thiswasespecially
true for people in the pulmonary category.4 Depression Research and Treatment
Table 3: Hazard ratios (95% conﬁdence interval (CI)) of benzodiazepines or antidepressant prescriptions in 2000-2004 for those without
such prescriptions in 1999.
Benzodiazapines Antidepressants
N Cumulative incidence Hazard ratio∗
N Cumulative incidence Hazard ratio∗
(%) (95% CI) (%) (95% CI)
Reference 390,050 25.1 1.00 439,658 9.3 1.00
Diabetes 8,990 26.3 1.08 (1.04–1.13) 10,384 11.1 1.25 (1.18–1.33)
Pulmonary 15,357 33.5 1.45 (1.41–1.49) 19,306 13.4 1.52 (1.46–1.58)
Cardiovascular 139,157 29.5 1.23 (1.22–1.25) 177,237 10.5 1.17 (1.14–1.19)
Multimorbidity 584,439 32.1 1.37 (1.34–1.40) 40,835 13.2 1.50 (1.46–1.55)
∗Hazard ratio adjusted for age and sex.
Table 4: Hazard ratios (95% conﬁdence interval (CI)) of benzodiazepines or antidepressant prescriptions in 2000–2004 for those without
such prescriptions in 1999, analysed separately for men and women and for persons younger and older than 65.
Hazard ratio∗ (95% CI) of incident benzodiazepines
prescriptions
Hazard ratio∗ (95% CI) of incident antidepressants
prescriptions
Men Women Men Women
(22.8% of 262,936 with
prescription)
(30.0% of with
prescription)
(8.0% of 292,267 with
prescription)
(11.5% of 395,135 with
prescription)
Reference 1.00 1.00 1.00 1.00
Diabetes 1.06 (1.00–1.13) 1.10 (1.04–1.16) 1.20 (1.09–1.32) 1.28 (1.19–1.38)
Pulmonary 1.44 (1.38–1.50) 1.46 (1.40–1.51) 1.48 (1.39–1.58) 1.57 (1.49–1.65)
Cardiovascul r 1.24 (1.22–1.27) 1.23 (1.21–1.25) 1.18 (1.14–1.21) 1.16 (1.13–1.18)
Multimorbidity 1.45 (1.41–1.50) 1.31 (1.27–1.35) 1.60 (1.52–1.68) 1.46 (1.41–1.51)
< 65 years (26.4% of
400,699 with prescription)
>= 65 years (27.4% of
183,740 with prescription)
< 65 years (9.9% of 454,579
with prescription)
>= 65 years (10.3% of
232,841with prescription)
Reference 1.00 1.00 1.00 1.00
Diabetes 1.10 (1.04–1.16) 1.09 (1.02–1.16) 1.29 (1.20–1.39) 1.24 (1.13–1.36)
Pulmonary 1.44 (1.39–1.49) 1.49 (1.42–1.57) 1.57 (1.50–1.65) 1.40 (1.40–1.61)
Cardiovascular 1.22 (1.20–1.24) 1.27 (1.25–1.29) 1.20 (1.17–1.23) 1.15 (1.12–1.18)
Multimorbidity 1.36 (1.32–1.40) 1.40 (1.36–1.44) 1.60 (1.53–1.67) 1.46 (1.40–1.52)
∗Hazard ratio adjusted for age and sex.
3.2. New Prescriptions for Benzodiazepines and Antidepres-
sants. From 2000–2004, ﬁrst-time prescriptions for benzo-
diazepines and antidepressants were provided to more than
25% and 10% of the total population, respectively. People
in the pulmonary and multimorbidity categories were more
likely to receive their ﬁrst prescription for these medications
than people in the other categories (about 8 and 4% more,
resp.).
Men in the multimorbidity category had (as compared
to their reference group) a greater chance of receiving
benzodiazepinesandantidepressantsthantheirfemalecoun-
terparts. With regard to age, we found only a somewhat
elevated chance for people younger than 65 years in the
multimorbidity and pulmonary categories as compared to
the over-65s in these categories, but only as regarding
prescriptions for antidepressants.
3.3. Trends in Repeat Prescriptions for Benzodiazepines.
People in the reference and diabetes categories generally
had the lowest chance of receiving repeat benzodiazepine
prescriptions, while those in the multimorbidity category
were at highest risk.
4. Discussion
Our cross-sectional and longitudinal analyses show a clear
associationbetweenpatientclassiﬁcationandthenumbersof
prescriptions for benzodiazepines and antidepressants. This
was true for both new and repeat prescriptions. Men with
prescriptions for physical chronic disease received more psy-
chotropic medication than women, as were people younger
than 65 compared to those older than 65, although women,
in absolute terms, received more prescriptions than men.
As far as new prescriptions were concerned, this was espe-
cially true for antidepressants but not for prescriptions for
benzodiazepines. Chronic psychotropic prescription showed
an almost linear association with classiﬁcation, with persons
belonging to the multimorbidity category having the lowest
percentages of people without 6–12 annual prescriptions
and those in the reference category having the highest.Depression Research and Treatment 5
Table 5: Frequency distribution of people with 6–12 benzodiazepines prescriptions per year according to the number of years with these
prescriptions in % (absolute numbers between brackets).
Number of years with 6–12 prescriptions
Grouping 0 1-2 3-4 5-6 Tot
Reference 93.8 4.0 1.2 1.0 100.0 (442.695)
Diabetes 93.4 4.2 1.3 1.2 100.0 (10.264)
Pulmonary 89.2 6.4 2.0 2.4 100.0 (18.523)
Cardiovascular 89.0 6.0 2.2 2.7 100.0 (169.764)
Multimorbidity 87.4 7.0 2.6 3.0 100.0 (37.534)
Total 92.1 4.7 1.6 1.6 100.0 (678.780)
These ﬁndings are in good agreement with data recently
published by LINH, a representative Dutch network of
77 general practices, showing that depressed people with
comorbidity are more often prescribed benzodiazepines and
antidepressants than depressed people without comorbidity
[19].
Our exploratory analysis suﬀered from some possible
pitfalls. First, we used an existing database not especially
designed for this study. Therefore, we can only perform
an exploration enabling the development of hypotheses
for further testing. Second, we used a rather crude and
indirect method to assess the presence of physical illness.
We could, for example, not exclude patients with diabetic
neuropathy who used antidepressants for other indications
than depressive disorder. In spite of this inaccuracy, it is
plausible that the trends we found are consistent and robust
and thereby reassuring regarding the validity. Furthermore,
as we could not select people with prescriptions for other
chronic conditions, the category without prescriptions for
diabetes, cardiovascular, or pulmonary disease probably
comprised patients with other chronic diseases, in addition
to healthy persons. Given the probable majority of people
without any chronic condition in this category, however,
any possible bias is assumed to be negligible and in the
worst case leading to an underestimation of the associations
we identiﬁed. We also tried to prevent bias by excluding
sections of the total population that might contribute to
invalid ﬁndings. The consistency of the ﬁndings of all our
analyses regarding the diﬀerence between the categories and
the comparability with the outcomes of other studies is in
any case reassuring. Secondly, we used rather crude age
categories. A clearer distinction between younger and older
people could have made the contrast between these two
categories sharper. For this reason, we controlled for age
diﬀerences within the two categories. Forth, we only used
the data of patients with compulsory coverage under the
Dutch state health insurance scheme, who tend to belong
to the lower socioeconomic groups in society. It is well-
known that prescription rates for people with relatively low
socioeconomic status are higher than those for people at the
highest socioeconomic levels.
Keepingthesepotentialpitfallsinmind,ourﬁndingslead
us to conclude that this analysis, with its rather robust out-
come,warrantsfurtherinvestigationandin-depthanalysisto
explain the associations found and to further investigate the
severityofdepressionandtheextenttowhichdrugtreatment
iscombinedwithpsychotherapyasrecommendedbyexisting
guidelines in Great Britain and the Netherlands. In patients
with subthreshold depression, a “wait and see” policy is
preferred as well as the use of behavioural interventions as
the ﬁrst choice approach for patients with incident non-
severe depressive and/or anxiety disorders [7, 8, 20]. The
most important reason for this recommendation is the lack
of eﬀectiveness of long-term use of benzodiazepines, and to a
less extent also antidepressants, in patients with mild mental
problems. Although anti-depressants have proved to be as
eﬀective as psychological strategies in patients with non-
severe depression, the latter seem to have better long-term
eﬀects [21].
Elderly people with chronic conditions seem to be
a particularly neglected group, as their mental problems
appear to be underdiagnosed very often in primary care
[11]. Many of those, who supposedly may have been
detected as having mental problems, were found to receive
benzodiazepine prescriptions very frequently and exceeding
a period of 6 months. Further research is needed to shed
light on this probable lack of compliance with the existing
guidelines. Are they too strict or might GP’s feel helpless,
because these patients are at permanent risk of depression
or mood disturbances, or might they feel that mental
problems are simply normal for the chronic condition The
reason why prescribing benzodiazepines for a maximum of
six weeks has become part of the guidelines is that the
use of these drugs over longer periods is not helpful and
even damaging, as it encourages dependency and passivity.
It is worthwhile to further investigate the reason for the
discrepancy between actual benzodiazepines prescription
patterns and the guidelines.
In the Netherlands, there probably is an increasing
tendency to treat mental problems, serious, and less serious
alike, with drugs [3]. On the other hand, many patients,
especially with a chronic physical disease, remain undetected
with their mental problems. With the increasing prevalence
of patients with a chronic physical condition, it might be
worthwhile to further investigate the existing practice of the
treatment of mental health problems in this group, especially
in primary care. This might provide insight into possibilities
to improve quality of mental health care and contribute to
improvement of the guidelines for the support of patients
with a chronic physical disease and mental problems.6 Depression Research and Treatment
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